The proven efficacy of Keppra XR™ gives patients the opportunity to reach and stay at the goal of epilepsy therapy.

Significant efficacy for partial-onset seizures established in a Phase III clinical trial1*

  • 12-week, multicenter, randomized, double-blind, placebo-controlled study of Keppra XR™ as adjunctive therapy in 158 patients with refractory partial-onset seizures
  • No titration period—patients took the starting dose of Keppra XR™ 1000 mg/day
    throughout the study
*Phase III, multicenter, double-blind, randomized, placebo-controlled, parallel-group study of patients 12 to 70 years of age with refractory partial-onset seizures. After a prospective baseline period of 8 weeks, 158 patients were randomized to receive either placebo (n=79) or Keppra XR™ 1000 mg/day (given as two 500-mg tablets once daily; n=79) over a 12-week treatment period. There was no titration period; patients took the starting dose of Keppra XR™ (1000 mg/day) throughout the study. The primary efficacy endpoint was the percent reduction over placebo in mean weekly frequency of partial-onset seizures over the treatment period.

10.1% of refractory patients achieved freedom from partial-onset seizures from the
FIRST DOSE of Keppra XR™ 1000 mg1

Partial-Onset Seizure Freedom From The First Dose Through The 12-Week Treatment Period
†Patients achieving 100% reduction in partial-onset seizures who completed the 12-week treatment period.

Keppra XR™ provided significant seizure reduction in refractory patients

  • 46.1% median reduction in weekly partial-onset seizure frequency with Keppra XR™ vs. 33.4% with placebo
    — The reduction over placebo in weekly partial-onset seizure frequency was
         statistically significant (14.4%; P=0.038)

More patients taking Keppra XR™ achieved ≥50% seizure reduction1

Seizure Frequency

REFERENCES

1. Data on file. UCB, Inc.